TP53 and cancer: Their assaying could providea potentially more robust and direct insight into cancer progressionand prognosis.12 Among the anti-p53 antibodies,the monoclonal DO-1 antibody is widely used in Western blotting, immunohistochemistry,and immunoprecipitation.5 It is known tobind to a relatively conserved six-residue epitope (SDLWKL) on theN-terminal transactivation domain (TAD) of p53.12 This region has been shown to be less prone to mutationcompared to the DNA-binding domain (DBD), making it a more consistentlyeffective target for antibodies regardless of p53 form.13